News
Novo Nordisk Names Maziar Mike Doustdar as President and Chief Executive Officer
Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief executive officer (CEO). Jørgensen will step down from his current role serving as president and CEO on the same day Doustdar is expected to take over.
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...
At the 78th World Health Assembly in Geneva, the Novo Nordisk Foundation has pledged up to DKK 380 million to the WHO for the period 2025-2028.
Novo Nordisk Foundation's nine-person board includes former Novo CEO and current board chairman Lars Rebien Sørensen, University of Copenhagen professor Liselotte Højgaard, Massachusetts ...
And outside the Novo Group, AstraZeneca made a push to reduce its environmental impact earlier this year, pledging $1 billion to go carbon-free by 2025, while Takeda CEO Christophe Weber said the ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
The Novo Nordisk Foundation has become a major philanthropic force as a result, with Novo Holdings’ €149 billion ($156 billion) in assets under management dwarfing the $75.2 billion endowment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback